Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EHA 2021 | Impact of genomics in the future of ALL treatment

Anthony Moorman • 8 Jun 2021
EHA 2021
Acute Lymphoblastic Leukemia Leukemia

Anthony Moorman, PhD, Newcastle University, Newcastle, UK, discusses how genomics research could impact the future direction of acute lymphoblastic leukemia (ALL) treatment, in particular talking on the benefits of risk stratification based on molecular subtypes to optimise treatment. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.

More from Anthony Moorman

Genomic profiling is redefining risk stratification in acute lymphoblastic leukemia
2:01
Genomic profiling is redefining risk stratification in acute lymphoblastic leukemia
Anthony Moorman • 13 Jun 2026
Predicting CNS relapse in ALL: integrating genetic and clinical risk factors
1:44
Predicting CNS relapse in ALL: integrating genetic and clinical risk factors
Anthony Moorman • 13 Jun 2026
Age and cytogenetics influence prognostic value of copy number profiles in B-cell ALL
1:48
Age and cytogenetics influence prognostic value of copy number profiles in B-cell ALL
Anthony Moorman • 12 Jun 2026
Future directions in ALL: targeted therapies and chemotherapy-free approaches
2:41
Future directions in ALL: targeted therapies and chemotherapy-free approaches
Anthony Moorman • 12 Jun 2026

Related Videos

Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
4:04
Addressing changes to genomic prognostic markers in CLL beyond the chemotherapy era
Anna Schuh • 16 Oct 2026
Understanding the CLL genome: current knowledge and remaining gaps
3:39
Understanding the CLL genome: current knowledge and remaining gaps
Anna Schuh • 16 Oct 2026
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
2:00
How is frontline fixed-duration acalabrutinib plus venetoclax shaping treatment decisions in CLL?
Alexey Danilov • 16 Oct 2026
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
3:39
Autoimmune cytopenias in patients with CLL on venetoclax-based therapy: outcomes from an ERIC study
Marta Coscia • 16 Oct 2026

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals